[Form 4] Kura Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Brian T. Powl, Chief Commercial Officer and director at Kura Oncology (KURA), reported receipt of 48,900 shares of common stock from a vesting equity award on 09/27/2025 at no cash price, increasing his beneficial ownership to 108,567 shares. On 09/29/2025 he sold 8,891 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes related to the vesting, leaving him with 99,676 shares beneficially owned. The Form 4 was submitted by a single reporting person and includes an attorney-in-fact signature on behalf of the reporting person.

Positive

• Vesting of 48,900 shares increased the reporting person's stake to 108,567 shares, indicating retention of equity by management.
• Sell-to-cover was limited to 8,891 shares at $8.9422, leaving a substantial remaining direct ownership of 99,676 shares.

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider received vested RSUs and completed a routine sell-to-cover tax sale; net holdings remain material.

The report documents a typical post-vesting sequence: an award of 48,900 shares vested and a partial disposition of 8,891 shares to cover tax obligations at $8.9422 per share. These transactions increased then adjusted the reporting person's direct ownership to 99,676 shares. The activity is administrative in nature and does not indicate discretionary cash sales beyond tax withholding.

Corporate Governance Expert

TL;DR: Filing reflects standard executive equity compensation mechanics with transparent reporting by an officer/director.

The Form 4 shows a vested RSU award followed by a sell-to-cover for tax obligations. The reporting person is identified as both an officer (Chief Commercial Officer) and a director, and the form was filed individually. The disclosure meets Section 16 requirements by reporting the acquisition and the related disposition, enabling investors to track insider alignment with shareholders.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Powl Brian T.

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

12730 HIGH BLUFF DRIVE, SUITE 400

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/27/2025		A		48,900	A	$0	108,567	D
Common Stock	09/29/2025		S(1)		8,891	D	$8.9422	99,676	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated 9/27/25.

	Thomas Doyle, Attorney-in-fact for Brian Powl	09/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did KURA insider Brian Powl report on Form 4?

The Form 4 reports receipt of 48,900 common shares from a vesting award on 09/27/2025 and a sale of 8,891 shares on 09/29/2025 as a sell-to-cover for taxes at $8.9422 per share.

How many KURA shares does Brian Powl beneficially own after these transactions?

After the vesting and sell-to-cover, the reporting person beneficially owned 99,676 shares of Kura Oncology common stock.

Why were 8,891 KURA shares sold by the reporting person?

The sale of 8,891 shares is explained in the filing as a sell-to-cover for taxes associated with the vesting of the RSU award dated 09/27/2025.

What role does the reporting person hold at Kura Oncology?

The reporting person is identified as a Director and the company's Chief Commercial Officer.

Was the Form 4 filed by multiple reporting persons?

No. The form indicates it was filed by one reporting person.